GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BioSig Technologies Inc (NAS:BSGM) » Definitions » Debt-to-EBITDA

BioSig Technologies (BioSig Technologies) Debt-to-EBITDA : -0.02 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is BioSig Technologies Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

BioSig Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.35 Mil. BioSig Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.10 Mil. BioSig Technologies's annualized EBITDA for the quarter that ended in Dec. 2023 was $-24.30 Mil. BioSig Technologies's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.02.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for BioSig Technologies's Debt-to-EBITDA or its related term are showing as below:

BSGM' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.03   Med: -0.02   Max: -0.01
Current: -0.02

During the past 11 years, the highest Debt-to-EBITDA Ratio of BioSig Technologies was -0.01. The lowest was -0.03. And the median was -0.02.

BSGM's Debt-to-EBITDA is ranked worse than
100% of 429 companies
in the Medical Devices & Instruments industry
Industry Median: 1.21 vs BSGM: -0.02

BioSig Technologies Debt-to-EBITDA Historical Data

The historical data trend for BioSig Technologies's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioSig Technologies Debt-to-EBITDA Chart

BioSig Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.02 -0.01 -0.02 -0.03 -0.02

BioSig Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -0.02 -0.01 -0.03 -0.02

Competitive Comparison of BioSig Technologies's Debt-to-EBITDA

For the Medical Devices subindustry, BioSig Technologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioSig Technologies's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BioSig Technologies's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where BioSig Technologies's Debt-to-EBITDA falls into.



BioSig Technologies Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

BioSig Technologies's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.349 + 0.103) / -28.151
=-0.02

BioSig Technologies's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.349 + 0.103) / -24.296
=-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


BioSig Technologies  (NAS:BSGM) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


BioSig Technologies Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of BioSig Technologies's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


BioSig Technologies (BioSig Technologies) Business Description

Traded in Other Exchanges
N/A
Address
55 Greens Farms Road, 1st Floor, Westport, CT, USA, 06880
BioSig Technologies Inc is a commercial stage medical device company. It is developing a proprietary technology platform to minimize noise and artifacts from cardiac recordings during electrophysiology studies and ablation.
Executives
Kenneth L Londoner director, 10 percent owner 10 RED COAT ROAD, WESTPORT CT 06880
Steven J Buhaly officer: Chief Financial Officer 1195 NW LOMPTON DRIVE, BEAVESTON OR 97006
John Sieckhaus officer: Chief Operating Officer C/O BIOSIG TECHNOLOGIES, 55 GREENS FARMS ROAD, WESTPORT CT 06880
Steve Chaussy officer: Chief Financial Officer 9780 E AVE, HESPERIA CA 92345
Patrick Joseph Gallagher director 275 PLEASANT HILL RD., FLANDERS NJ 07836
Gray Fleming officer: Chief Commercial Officer C/O BIOSIG TECHNOLOGIES, INC., 55 GREENS FARMS ROAD, WESTPORT CT 06880
James L Klein director 2300NE BROOKWOOD PKWY, HILLSBORO OR 97124
Frederick Hrkac director C/O BIOSIG TECHNOLOGIES, 55 GREENS FARMS ROAD, WESTPORT CT 06880
James J Barry director C/O INSPIREMD, INC., 4 MENORAT HAMAOR ST., TEL AVIV L3 6744832
Jeffrey F Odonnell director 126 ROSSMORE DRIVE, MALVERN PA 19355
Anthony P. Zook director C/O VIVUS, INC., 351 EAST EVELYN AVENUE, MOUNTAIN VIEW CA 94041
Jerome B Zeldis director 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Martha Pease director 33 SEAVIEW, MADISON CT 06443
John M Kowalski officer: VP of Sales 54 WILTON ROAD, 2ND FLOOR, WESTPORT CT 06880
Samuel E Navarro director C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044

BioSig Technologies (BioSig Technologies) Headlines